Y.D. More Investments Ltd Boosts Position in Brainsway Ltd. Sponsored ADR $BWAY

Y.D. More Investments Ltd raised its position in Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) by 136.6% during the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 272,004 shares of the company’s stock after acquiring an additional 157,042 shares during the quarter. Y.D. More Investments Ltd’s holdings in Brainsway were worth $3,615,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Raymond James Financial Inc. bought a new stake in shares of Brainsway during the 2nd quarter valued at about $85,000. Bank of America Corp DE bought a new position in shares of Brainsway in the 3rd quarter worth approximately $107,000. Royal Bank of Canada boosted its holdings in shares of Brainsway by 1,145.9% in the fourth quarter. Royal Bank of Canada now owns 8,410 shares of the company’s stock worth $160,000 after buying an additional 7,735 shares during the last quarter. Nano Cap New Millennium Growth Fund L P purchased a new stake in Brainsway during the fourth quarter valued at approximately $209,000. Finally, Centiva Capital LP bought a new position in Brainsway in the third quarter worth approximately $181,000. 30.11% of the stock is owned by hedge funds and other institutional investors.

Brainsway Stock Performance

Shares of BWAY stock opened at $15.06 on Monday. The stock has a market capitalization of $604.36 million, a price-to-earnings ratio of 43.03 and a beta of 1.22. Brainsway Ltd. Sponsored ADR has a 12-month low of $5.68 and a 12-month high of $17.35. The stock’s 50-day moving average price is $15.20 and its 200-day moving average price is $13.55.

Brainsway (NASDAQ:BWAY) last released its quarterly earnings results on Wednesday, May 13th. The company reported $0.12 earnings per share for the quarter, beating the consensus estimate of $0.05 by $0.07. The business had revenue of $15.53 million during the quarter, compared to analysts’ expectations of $14.63 million. Brainsway had a return on equity of 12.28% and a net margin of 15.68%. As a group, research analysts predict that Brainsway Ltd. Sponsored ADR will post 0.33 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

BWAY has been the subject of a number of recent research reports. Weiss Ratings raised shares of Brainsway from a “hold (c)” rating to a “buy (b-)” rating in a research report on Friday, April 24th. Wall Street Zen raised Brainsway from a “hold” rating to a “buy” rating in a report on Saturday, June 13th. Zacks Research cut shares of Brainsway from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 11th. Finally, HC Wainwright restated a “buy” rating and issued a $17.00 price objective on shares of Brainsway in a research report on Thursday, July 2nd. Three equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, Brainsway has an average rating of “Moderate Buy” and a consensus price target of $16.00.

Brainsway Company Profile

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.